Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for 4D Molecular Therapeutics (FDMT) over the last 1 years, with Dec 2019 value amounting to $103.0 million.

  • 4D Molecular Therapeutics' Preferred Stock Liabilities was N/A to $103.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $103.0 million, marking a year-over-year change of. This contributed to the annual value of $103.0 million for FY2019, which is N/A change from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Preferred Stock Liabilities of $103.0 million as of FY2019.
  • In the past 5 years, 4D Molecular Therapeutics' Preferred Stock Liabilities registered a high of $103.0 million during FY2019, and its lowest value of $103.0 million during FY2019.
  • In the last 1 years, 4D Molecular Therapeutics' Preferred Stock Liabilities had a median value of $103.0 million in 2019 and averaged $103.0 million.